Miguel Varela
GROUP LEADER - DRUG DELIVERY
Miguel leads a research group at the Institute of Development and Regenerative Medicine and connects AI agents with the physical world, translating their digital power into practical outcomes that enable future visionary scientists and entrepreneurs.
His research interests focus on:
#1 discovery of novel therapeutic targets.
#2 the development of new delivery systems for RNA therapy.
#3 studying the interface of the immune system with the pathology of neuromuscular and cardiac diseases.
Recent publications
-
TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhibition.
Torres P. et al, (2024), Acta Neuropathol, 148
-
Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression.
González-Martínez I. et al, (2023), Mol Ther Nucleic Acids, 34
-
Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1.
Stoodley J. et al, (2023), Int J Mol Sci, 24
-
A modular RNA delivery system comprising spherical nucleic acids built on endosome-escaping polymeric nanoparticles
Garcia-Guerra A. et al, (2023), Nanoscale Advances
-
Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy.
Stoodley J. et al, (2023), Methods Mol Biol, 2587, 209 - 237